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Abstract
Objective—Chronic, low-level inflammation is associated with symptomatic bipolar disorder 
(BD) and with chronic insomnia. Disrupted sleep is a feature of episodes of both mania and 
depression. We examined the effect of neopterin, a marker of cellular immune activation, and 
kynurenine (KYN), an inflammatory by product of the serotonin pathway, on the association 
between total sleep time and depression severity in BD.
Method—Twenty-one symptomatic BD participants and 28 healthy controls (HC) were recruited 
and followed during usual clinical care. At baseline and after symptomatic recovery, total sleep 
time was objectively measured with actigraphy for one week and blood plasma was collected to 
measure the serotonin-precursor tryptophan (TRP), KYN, KYN/TRP ratio and neopterin levels. 
Statistical analyses were conducted using chi square, independent t-tests and hierarchical linear 
multiple regression models.
Results—Total sleep time was positively correlated with depressive severity and negatively 
correlated with manic severity. TRP was significantly reduced in BD participants compared to HC. 
KYN, TRP, and the KYN/TRP were associated with depressive severity when total sleep time and 
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BMI were included in the model. The KYN/TRP ratio trended towards a negative association with 
mania symptoms, controlling for BMI and total sleep time, in acutely symptomatic BD 
participants. Neopterin was not associated with sleep or mood severity. After usual clinical care, 
BD participants showed significantly decreased clinical symptoms but no significant differences in 
sleep phenotype or biomarkers.
Conclusion—Inflammation, sleep and mood are closely intertwined. Future research into the 
effect of inflammation on sleep in BD may lead to clinical markers of outcome.
Introduction
Bipolar disorder (BD) is a severe psychiatric disorder, with a complex and sometimes 
heterogeneous range of symptoms.1 BD is one of the leading causes of disability 
demonstrating on average a less favorable prognosis than individuals with major depressive 
disorder (MDD).2 As a clinically heterogeneous syndromic disorder, the biological changes 
in BD have been reported in depressive and manic episodes, and any unifying biological 
underpinnings of this disorder have remained elusive. 3–5 Research shows that BD presents 
with numerous immune-inflammatory and sleep abnormalities. 6–8 Activation of the 
kynurenine (KYN) pathway has been supported in a number of psychiatric disorders, 
including BD 9, 10.While many studies have independently explored sleep,11–13 
inflammation,7, 14 and the KYN 9, 15 pathway in BD, there is increasing evidence that 
inflammation is an important factor in mood, stress, and sleep disturbance 16, 17 and needs to 
be examined simultaneously for a better understanding of the underlying biological 
mechanisms. Additionally, there is a dearth of research exploring inflammation, metabolites 
of the KYN pathway or sleep in acutely ill BD patients. 4
Mood spectrum disorders (BD, recurrent depressive disorder and seasonal affective disorder) 
are accompanied by sleep dysregulations that are particularly common among bipolar 
participants.8, 12, 13, 18 Sleep dysregulations in mood disorders commonly occur in acute 
manic or depressive states but are also prevalent during remission. 8, 19–21 A meta-analysis 
focusing on sleep in remitted BD participants highlights disturbances in several sleep 
parameters: longer sleep latency, longer sleep duration, and poorer sleep efficiency.21 Sleep 
is a remarkably sensitive, but not very specific, indicator of distress and dysregulated sleep 
can occur for a variety of reasons. Inflammation has been shown to be associated with sleep 
disturbance and objective short sleep in primary insomnia and obstructive sleep apnea, and 
may mediate the association between sleep apnea and adeposity.22–24 By examining the 
association of sleep dysregulation to inflammatory biomarkers in BD, we may gain an 
understanding of the sleep, mood and inflammation connection.
The essential amino acid tryptophan (TRP) is a substrate for two important biosynthetic 
pathways: the serotonin (5-HT) pathway and the KYN pathway (Figure 1). During stress, 
proinflammatory cytokines activate the KYN pathway; deprive the 5-HT pathway of TRP, 
thereby reducing 5-HT synthesis. The dynamics of this process are characterized best by the 
kynurenine-to-tryptophan (KYN/TRP) ratio. One of the inflammatory drivers of this 
diversion of 5-HT to KYN is neopterin, a catabolic product of guanosine triphosphate that is 
a marker of cellular immune system activation produced by macrophages upon stimulation 
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by interferon-gamma. 25–28 Increased peripheral KYN results in increased central KYN. 
KYN is further broken down into quinolinic acid, which potently agonizes the N-methyl-D-
aspartate (NMDA)-receptor causing excitotoxic effects through receptor over-activation 
29, 30
 and inhibits glutamate uptake that causes elevated extracellular glutamate 
concentrations. 31
In the current study, we investigated the relationship between markers of the KYN pathway, 
neopterin, sleep and clinical symptoms in acutely ill BD participants. We were also 
interested in exploring biomarkers and sleep patterns after symptom remission to determine 
whether these biomarkers were potentially state vs. trait characteristics independent of mood 
state. We hypothesized:
1) Individuals with acute BD would have significantly lower total TRP and higher 
KYN/TRP ratio and neopterin levels than healthy controls (HC).
2) TRP, KYN/TRP and neopterin would be associated with severity of depressive 
and manic symptoms in acutely symptomatic participants with BD.
3) Sleep duration and biomarkers including kynurenine pathway metabolites (TRP, 
KYN/TRP), and the pro-inflammatory cytokine neopterin would be associated 
with depressive and manic symptom severity.
Finally, we were interested in whether these markers changed with symptom remission in 
asymptomatic patients and explored differences in clinical symptoms, sleep and biomarkers 
between baseline and follow up.
Participants and Methods
Participants
Thirty BD participants with current mood symptoms participated in the study, and twenty-
one completed all measures for this analysis. Participants were recruited when presenting for 
inpatient or partial hospital care at the Pennsylvania Psychiatric Institute, under Institutional 
Review Board Protocol No. 39164EP and NIH Office of Human Subject Research 
Exemption #11509 (7/16/2012). Participants were screened and consented for the study and 
assessments including sleep and biomarkers were administered while they were receiving 
inpatient or partial hospital care. Inclusion criteria for BD participants included adults with a 
primary diagnosis of BD I or II. Exclusion criteria included use of non-steroidal anti-
inflammatory drugs (NSAIDS) on a daily basis, active substance intoxication or withdrawal, 
major endocrinological or rheumatological illness or pregnancy. Twenty eight healthy 
control (HC) participants were recruited via advertisement based on the inclusion criteria 
that they had with no personal or family history of mental illness, rheumatologic or 
endocrine illness, pregnancy, daily NSAIDS or aspirin use. HCs provided actigraph data in 
their home environment while clinical and blood measures were collected at the research 
site.
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Measures
Structured clinical interview based on the Mini Neuropsychiatric Interview 32 were 
conducted and current mood state was assessed with the Hamilton Depression Rating 
Scale-21 plus atypical items (HDRS-21 + AT) 33, and the Clinician-Administered Rating 
Scale for Mania (CARS-M). 34 A combination of clinically significant manic and depressed 
symptoms defined a mixed-manic phenotype. HDRS-21 + AT scores between 0 and 6 
indicated no depression, scores between 7 and 17 indicated mild depression, scores between 
18 and 24 indicated moderate depression, and scores over 24 indicated severe depression. 
CARS-M scores below 7 were considered not manic. Scores between 7 and 12 were mild, 
and above 12 were severe manic phenotypes. Body Mass Index (BMI) for each participant 
was calculated by measuring height and weight. Participants received usual clinical care and 
were discharged from the program. After discharge from the hospital or partial hospital 
program, participants were followed each week by phone and assessed for clinical 
improvement. A return visit was scheduled to collect a second blood sample when the 
subject was asymptomatic, or after 3 months had elapsed. Additional measures were 
collected but not used for this analysis. For more detailed report on methods and results of 
analysis of fatty acid concentrations, please see Saunders, et al. 35
Objective measure of Total Sleep Time
During the period of initial evaluation, participants wore an actigraph (Sleepwatch-O, 
Ambulatory Monitoring, Inc., Ardsley NY), a watch-like device that measures acceleration, 
on the non-dominant hand for 7 days. Participants also maintained a sleep log, which 
combined with the actigraphy recording, provides accurate measure of objective sleep 
measures. ActiLife V.6.4.5 software (ActiGraph Software Department, Pensacola, FL) was 
used to compute the actigraphy sleep variables, including total sleep time, bedtime 
variability, sleep latency, sleep duration, and sleep efficiency. BD participants completed the 
actigraph during hospitalization and HCs completed it at home. Due to the small sample 
size, we limited analysis the analysis of sleep variables to the investigation of total sleep 
time only, which allowed us to conserve statistical power. However, an additional 
exploratory analysis of mean lag (variability in bedtime from night to night) was also made.
Sample collection and biochemical analysis
Participants fasted for at least 6 hours, and blood was drawn in vacutainers containing EDTA 
in the morning. BD participants had blood drawn between 7:15 and 10:30 AM (average time 
was 8:24 AM) and HC participants had blood drawn between 8:00 AM and 2:00 PM 
(average time was 9:19 AM). After centrifugation for 10 min at 654.03 g, the plasma 
supernatant was transferred to plastic tubes and maintained at −80°C until processed. Total 
TRP (micromoles per liter) and KYN (micromoles per liter) were measured by reversephase 
high-performance liquid chromatography, as previously described 36, 37, using 3-nitro-L-
tyrosine as an internal standard. The KYN/TRP ratio was calculated (expressed as 
micromoles of KYN per millimoles of TRP). Neopterin was measured by enzyme-linked 
immunosorbent assay (BRAHMS, Hennigsdorf, Germany) according to the manufacturer’s 
instructions, with a detection limit of 2 nmol/L.
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Data and statistical analysis
SPSS version 22, IBM SPSS Statistics (IBM Corporation, Armonk, NY, USA) was used for 
all statistical calculations. Values of continuous variables were compared between the BD 
and HC groups using independent samples t-tests, and categorical variables were compared 
using the Pearson chi-square test. Paired t-tests were used for baseline and follow-up 
measurements. In an exploratory analysis, Pearson’s r was used for separate bivariate 
correlations on demographics and clinical symptoms, sleep and inflammation variables in 
the BD sample and the HC sample. Baseline depression was predicted using linear 
regression models based on a priori variables, controlling for BMI due to the known 
association between inflammation and obesity.38 Model one included total sleep time and 
KYN/TRY, model two, total sleep time and KYN, model three included total sleep time and 
TRP and model four had total sleep time and neopterin as predictor variables. The same 
models were implemented to predict baseline manic symptoms controlling for BMI. Paired 
t-tests were conducted to compare symptoms, total sleep time and inflammatory variables 
from baseline to follow-up. However, considerably fewer participants were present in 
follow-up data. This was due to inability to maintain regular contact with some participants 
due to a number of issues (e.g., such as unstable housing conditions) (the maximum number 
of days to follow up was 187; the median was 22 days and average was 52 days). An 
analysis of dropouts vs. those who continued to be a part of the study, however, did not show 
any significant differences based on baseline clinical symptoms and demographics including 
age and sex (p values >.16). Dependent variables were compared between BD smokers and 
non-smokers with independent t-tests.
Results
Demographic and clinical description of the sample
A cohort of 30 participants with BD was recruited while in a symptomatic mood episode. 
Six participants did not have sleep assessment data, and 3 did not have biomarker data, thus 
21 BD participants were included in the final analysis. A parallel HC group of 31 
participants was recruited for the study, of which three participants did not have sleep data 
(n=28). Participants with BD did not differ in age, gender, race, from the HC group (Table 
I). A significantly higher proportion of participants with BD were unemployed, not married 
and smokers than the HC group (Table I). Independent t tests were run between the smokers 
and non smokers within the BD group to detect any differences based on age, BMI, HRSD, 
CARSM, TRP, KYN, KYN/TRP and sleep variables. No differences were detected with all p 
values above .10.
Clinically, BD individuals had a significantly higher BMI and when evaluated for the study, 
exhibited, on average, severe depressive symptoms and moderate manic symptoms (Table I).
Sleep and Inflammation Variables
The HC group slept an average of 6.9 hours, with a standard deviation of about an hour; and 
the mean difference in mean lag (variability in bedtime from night-to-night) was 4 minutes 
with a standard deviation of one hour. The BD group slept an average of 6.5 hours, with a 
standard deviation of almost two hours; and the mean lag was 23 minutes, with a standard 
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deviation of 60 minutes. Total sleep time was positively correlated with depressive symptom 
severity and negatively correlated with the severity of manic symptoms (Table II).
1) Group comparisons of TRP, KYN/TRP, and neopterin: As hypothesized, the BD group 
had significantly lower levels of TRP than healthy controls (p <.03) (Table I). The BD group 
did not significantly differ from the HC group in mean levels of KYN, KYN/TRP and 
neopterin (Table I).
2)TRP, KYN/TRP and neopterin and severity of depressive and manic symptoms: Based on 
Pearson’s correlation test, KYN, KYN/TRP, and neopterin did not correlate significantly 
with depressive and manic symptoms as measured by the HDRS and CARSM clinical 
measures or sleep measures including total sleep time and bedtime variability. None of the 
kynurenine pathway markers were associated with total sleep time in either the BD or HC 
control group. Neopterin levels positively correlated with KYN/TRP (r = .53, p <.01), but 
were not correlated with clinical severity, TRP and KYN.
3) Association of biomarkers and sleep with depressive and manic severity: The association 
of depressive severity was tested with four hierarchical regression models using depressive 
severity as the dependent variable and total sleep time, KYN, TRP and KYN/TRP as the 
predictor variables controlling for BMI (Table IV). Depressive severity was significantly 
associated with KYN (model 3) and TRP (model 4), when total sleep time and BMI were 
accounted for. Models 3 and 4 (Table IV) accounted for 71% and 60% of the variance 
respectively. Model 1 consisting of KYN/TRP and total sleep time trended toward 
significance accounting for 60% of the variance (Table IV). Although total sleep time was 
significantly associated with manic severity in all four models, only the KYN/TRP 
biomarker trended towards significance (Table V). This model explained 35% of the 
variance (Table V).
Follow-up data
Exploratory analysis of the follow-up data showed that although the BD participants 
reported significantly decreased clinical symptoms of depression and mania, 35 no 
significant differences were detected in total sleep time, TRP, KYN/TRP. Total sleep time 
appears to have increased at follow-up but was not significantly different from baseline 
scores. This maybe due to the high variability in total sleep time score for BD participants 
(Table VI).
Discussion
The current study examined the relationship between objective markers of sleep and 
biomarkers of TRP metabolism and inflammation in a group of acutely symptomatic BD 
individuals. We found significantly lower levels of TRP in BD patients compared to HC. We 
also found that biomarkers, in conjunction with total sleep time, were positively associated 
with depressive severity and negatively associated with manic severity in BD patients.
Our first question addressed whether there were group differences between BD and HC in 
total sleep time, TRP and KYN/TRP. Our finding of lower TRP levels in acutely 
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symptomatic BD participants is concordant with several recent reports examining TRP 
levels in BD and schizophrenia 10, 39, 40 and the theory that decreased plasma TRP levels in 
BD participants may potentially lead to dysfunctional brain serotonin synthesis and release. 
Tryptophan depletion studies 41, 42 provide a useful tool to examine the role and association 
of serotonin in different psychiatric disorders. Most of the tryptophan depletion studies have 
focused on unipolar depression due to decreased serotonin as an underlying cause. For 
example, tryptophan depletion has been associated either with no effect 43 or with a slight 
but insignificant relapse of manic symptoms in fully recovered BD patients. No tryptophan 
depletion studies have been carried out in acutely manic BD patients. 39 The present study 
provides evidence for decreased tryptophan levels in naturalistic occurrence of acute mood 
episodes. While experimental studies support the notion that decreased levels maybe a 
precursor to a depressed mood state, however, in our study it is unclear whether the 
decreased tryptophan levels preceded or resulted from an acute mood state.
Second, we asked if the TRP, KYN/TRP, and neopterin were associated with severity of 
depressive and manic symptoms. We did not find neopterin, an inflammatory marker, to be 
significantly different from controls nor was it associated with depression or mania severity. 
Neopterin levels, however, were positively associated with KYN/TRP, which replicates 
earlier studies investigating depression and chronic inflammation.4445 Further mechanism 
studies examining the role of neopterin in mood disorders are warranted. For example, one 
study 25 found significantly higher levels of neopterin predicted post stroke depression in 
patients who had previously experienced a major depressive episode. Another cross-
sectional study found a positive association between MDD with a history of suicide attempt 
and KYN and but no association with neopterin .44 However, similar to our findings, 
Sublette et al. 44 found a positive correlation of the cytokine activation marker neopterin 
with KYN/TRP, suggesting that KYN production may be influenced by inflammatory 
processes. The present study supports previous studies finding an association between 
neopterin and KYN/TRP ratio but does not support a direct association between neopterin 
and mood disorders.
We hypothesized a significant association between sleep duration and biomarkers (TRP, 
KYN/TRP, neopterin) with depressive and manic symptom severity. Tryptophan degradation 
follows one of two main metabolic pathways, which ultimately lead to the production of 
either serotonin and melatonin, or kynurenine and its metabolites (Fig. 1). Enhanced 
activation of the kynurenine pathway due to stress or an acute mood state would 
theoretically hinder melatonin production, thereby potentially affecting sleep patterns of 
patients. 6, 46, 47 Thus activation of the kynurenine pathway potentially suggests the 
association of sleep and the kynurenine metabolites with mood states. While we did not find 
a correlation between these biomarkers and severity, we found an association with severity 
of clinical mood symptoms when considering KYN/TRP in conjunction with objective total 
sleep time. Neopterin and tryptophan degradation, as measured by the KYN/TRP is highly 
associated with immune activation which in turn leads to production of KYN instead of 5-
HT from TRP,48 but in our data neopterin, although correlated with KYN/TRP, was not 
associated with mood severity, with or without accounting for sleep. The association of 
KYN and TRP and total sleep time with severity of depression and manic symptoms implies 
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that these pathways are related but further research is necessary to delineate exactly how 
they influence each other.
Finally, we asked whether total sleep time, TRP and KYN/TRP changed with symptom 
remission in asymptomatic BD patients. Despite subjectively reported decreased clinical 
symptoms, no differences are detected in the biomarkers or total sleep time. One explanation 
could be the short follow-up time – perhaps these markers change on a slower time scale, or 
they may leave a long-term residual mark of the episode, indicating a change in physiology 
despite remission. 49–51
The results, however, need to be treated with caution due to the small sample size of the 
study. Additionally, the patients were all receiving medication for an acute mood episode 
which makes it difficult it to parse out the effects of medication. Third, in order to maximize 
statistical power the study investigated only one sleep variable –total sleep time. Sleep, 
however, is a complex phenomenon and consists of multiple aspects which are easily 
measured using actigraphic devices. Based on the results of the present study, different sleep 
variables along with inflammatory markers warrant further investigation with a larger 
sample size. Another important methodological factor is a structured hospitalized setting 
compared to a home environment. It may be argued that a hospitalized setting led to patients 
feeling more stressed than the control individuals, however, we argue that the patients were 
already in acute distress unable to cope with their existing resources leading to inpatient 
hospitalization. The structured setting of the hospital often relieves stress through learning 
basic skills and teaching patients to generalize those skills to real world naturalistic settings. 
52
Conclusion
In conclusion, the study provides evidence supporting the association of mood severity in 
acutely symptomatic BD participants with metabolites of the KYN pathway, in association 
with objective measurements of sleep. Further understanding of the role of in BD is 
important for development of potential targets for intervention, or markers of treatment 
response. Targeting sleep and regulation of the TRP breakdown pathway for intervention in 
BD participants is an area of research warranting further investigation. Targeting these areas 
for improvement and observing clinically significant changes may lead to more sustained 
improvement and remission rates.
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Figure 1. 
The Kynurenine Pathway
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Table I
Demographic, Clinical Symptoms and Differences in Sleep and Biomarkers between Healthy Controls and 
Bipolar Disorder Individuals
Healthy
Control
Bipolar
Disorder
N (%) N (%) P
Total sample size 28 21
Sex (F) 16 (57%) 10 (48%) 0.57
Race
  Asian 3 (11%) 0 0.19
  Black 1 (4%) 0
  White 24 (86%) 21 (100%)
Marital Status 0.02
  Married 14 (50%) 4 (18.2%)
  Not married 14 (50%) 17 (81.8%)
Employment <0.001
  Unemployed 2 (7%) 11 (55%)
  Disabled 0 4 (20%)
  Employed 16 (57%) 4 (20%)
  Student 10 (36%) 1 (5%)
Smoking Status 1 (4%/) 11 (52%) <.001
Mean (SD) Mean (SD)
Age (in yrs) 31.57 (10.33) 36.10 (11.33) 0.16
Body Mass Index(kg*m−2) 25.01 30.32 .001
(4.91) (5.49)
Mania (CARS-M) 0 16.52 <.001
(13.87)
Depression (H-21) .32 (.61) 33.62 <.001
(15.37)
Total Sleep Time (mins) 414.68 392.56 .45
(70.98) (117.23)
Bedtime variability (mins) −3.67 −22.62 .26
(58.31) (61.17)
KYN (µmol/L) 1.98 1.79 .22
(.55) (.50)
TRP (µmol/L) 68.74 60.25 .03
(11.62) (14.30)
KYN/TRP 28.93(7.26) 29.88(6.21) .63
Neopterin (nmol/N) 5.45 (1.39) 5.80 (1.66) .46
Note. KYN = Kynurenine, TRP = Tryptophan, Kyn/Try= Kynurenine/Tryptophan
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Table IV
Depressive symptom severity is positively associated with Total Sleep Time and KYN/TRP in Bipolar 
Disorder (controlling for BMI)
Variable β t R Adj.R2
Model 1 .81 .60
BMI .05 .34
Total Sleep Time .85 5.42**
KYN/TRP .32 2.0^
Model 2 .54 .24
BMI .50 3.85**
Total Sleep Time .27 2.15*
Neopterin .17 .92
Model 3 .85 .71
BMI .21 1.53
Total Sleep Time .78 5.88**
KYN .39 2.93**
Model 4 .81 .60
BMI .30 1.83
Total Sleep Time .66 4.53**
TRP .35 2.10*
Note. N = 21
*p < .05
**p < .01
^
=.06; BMI = Body Mass Index, Kyn/Try = Kynurenine/Tryptophan
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Table V
Manic symptom severity is negatively associated with Total Sleep Time and KYN/TRP in Bipolar Disorder 
Group (controlling for BMI)
Variable β t R Adj.R2
Model 1 .66 .35
BMI .04 .19
Total Sleep Time −.69
−3.59*
KYN/TRP −.39
−2.00^
Model 2 .40 .10
BMI .17 1.21
Total Sleep Time −.29
−2.12*
Neopterin .12 .90
Model 3 .60 .25
BMI −.21 −.57
Total Sleep Time −.57
−2.97*
KYN −.21 −1.07
Model 4 .57 .21
BMI −.06 −.28
Total Sleep Time −.56
−2.76*
TRP .05 .20
Note. N = 21
*p < .05
^p = .06
BMI = Body Mass Index, Kyn/Try = Kynurenine/Tryptophan
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Table VI
Paired sample t test comparing clinical symptoms of depression, mania, sleep and inflammation variables at 
baseline and follow up in BD
Baseline Follow Up N P Value
Mania 19.69 3.75 16 <.001
(15.11) (5.47)
Depression 32.40 11.13 15 <.001
(14.32) (10.60)
Total Sleep Time (minutes) 353.34 421.51 8 .24
(124.68) (125.70)
KYN (µmol/L) 1.69 1.70 13 .92
(.48) (.50)
TRP (µmol/L) 61.24 62.04 13 .82
(15.91) (13.78)
KYN/TRP 27.81(5.65) 27.34(5.81) 13 .82
Note. Kry/Try = Kynurenine/Tryptophan
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